%0 Case Reports
%T H2AFY is a novel fusion partner of MECOM in acute myeloid leukemia.
%A Han Q
%A Lu J
%A Wang J
%A Ye J
%A Jiang X
%A Chen H
%A Liu C
%A Chen L
%A Lin T
%A Chen S
%A Sun M
%A Gao F
%J Cancer Genet
%V 222
%N 0
%D 04 2018
%M 29666008
暂无%R 10.1016/j.cancergen.2018.01.004
%X The MECOM gene encoding a zinc finger protein that functions as a transcription factor, was located on chromosome 3q26, and rearrangements of MECOM often cause its overexpression in acute myeloid leukemia (AML). We identified H2AFY as a novel fusion gene partner of MECOM in an elderly male AML patient with cryptic 3q26 rearrangement using the whole transcriptome sequencing, who carried out abnormal karyotype of 46,XY,t(3;5)(q27;q31),add(14)(p11). We validated the existence of the unreported H2AFY-MECOM fusion gene by RT-PCR and Sanger DNA sequencing, and detected mutations of NRAS and BCOR in this patient. In addition, we found abnormally elevated expression of MECOM in this patient by quantitative-polymerase chain reaction (RQ-PCR). Further research is needed to investigate functional characterizations of this novel fusion in the development of AML.